CClinicalTrials.gg
Status unknownNCT05696340AJILITTUpdated Jan 25, 2023

Access to Pediatric Rheumatology Centers for JIA Patients: Factors Associated With Time to Access Pediatric Rheumatology Centers

An observational study in Juvenile Idiopathic Arthritis, sponsored by University Hospital, Clermont-Ferrand. Status unknown at 4 sites in France. Open to participants aged 11 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-25.

Sponsored by University Hospital, Clermont-Ferrand · Observational

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Other
Enrollment
45
Ages
11 Years and older
Sex
All
01

Study summary

JIA patients, their parents, and the health care professionals experience the complexity of the initial care pathway. The aim of the study is to explore the referral pathway to access pediatric rheumatology centers for JIA patients. The exploration will aim to identify the barriers and facilitators of referral, based on the conceptual framework of the health literacy. The investigators will conduct a qualitative study using semi-structured interviews. The perspectives of parents/children/health care professionals will be crossed to enrich the data.

02

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

Keywords

  • qualitative research
  • access to care
  • time to referral
  • health literacy
03

In context

Arthritis, Juvenile

352 studies on the registry are indexed under Arthritis, Juvenile; 92 are open to participants now.

This study's planned enrollment of 45 is below the median of 120 across 113 observational studies indexed under Arthritis, Juvenile.

Browse Arthritis, Juvenile studies →

Lead sponsor

University Hospital, Clermont-Ferrand is the lead sponsor of 841 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
11 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Children, adolescents, their parents, and the health care professionnals who have experienced the initial care pathway for JIA (between symptom onset and first visit with a pediatric rheumatologist).

Inclusion criteria

Children:

  • age > 11 years
  • JIA diagnosed between 4 and 24 months prior to the start of the study

Parents:

  • parent of a child with JIA diagnosed between 4 and 24 months prior to the start of the study

Health care professional:

  • Physician with experience in the initial management of children with JIA (between symptom onset and first visit with a pediatric rheumatologist).

Exclusion criteria

Exclusion Criteria:

For all participants:

  • Refusal to participate in interviews
  • Presenting a health condition incompatible with an interview
  • Participants with inadequate French to take part in semi-structured interviews
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
45 participants (estimated)
Patient registry
No

Groups and cohorts

  • JIA patients

    Children diagnosed with JIA between 4 and 24 months before the start of the study, treated and followed in a pediatric rheumatology center (old enough to answer the questions)

    Other: semi-structured interview

  • Parents of JIA patients

    Parents of a child diagnosed with JIA between 4 and 24 months prior to the start of the study (treated and followed in a pediatric rheumatology center)

    Other: semi-structured interview

  • Health care professionals

    Physician with experience in the initial management of JIA patients (between symptom onset and first visit with a pediatric rheumatologist)

    Other: semi-structured interview

Interventions

  • Othersemi-structured interview

    Subjects will be recruited in a purposive, non-randomized manner. Data will be collected to obtain a sufficient diversity of perspectives on the topic, while maintaining sufficient homogeneity for analysis. The number of participants cannot be determined in advance; it will be determined after data saturation.

06

What researchers measure

Primary outcomes

  1. Experience and views of barriers and solutions to the referral to pediatric rheumatology center for JIA patients

    Through semi-structured interviews, the study will reconstruct the referral pathway to the pediatric rheumatology center for JIA patients. * For patients and their parents, the interviews will focus on their experiences of the health care system, their feelings about interactions with health professional, their expectations and the elements that led to the parents' decision regarding their child's health. * For health care professionals, the interviews will focus on their experience in managing children with JIA (from the symptom onset to the first visit with the pediatric rheumatologist), the difficulties they encountered, and the improvements to be made in training and communication.

    Time frame: About 1 hour

07

Study locations

2 of 4 sites recruiting
  • CHU de Clermont-Ferrand
    Clermont-Ferrand, 63000, France
    • Etienne MERLIN · Principal investigator
    • Stephane ECHAUBARD · Sub investigator
    Recruiting
  • Hospices Civils de Lyon
    Lyon, France
    • Alexandre BELOT · Principal investigator
    Not yet recruiting
  • APHP
    Paris, France
    • Caroline FREYCHET · Principal investigator
    Not yet recruiting
  • Hopital Nord Franche-Comté
    Trévenans, France
    • Anne LOHSE · Principal investigator
    Recruiting
08

References and documents

Publications

  • Chausset A, Pereira B, Echaubard S, Merlin E, Freychet C. Access to paediatric rheumatology care in juvenile idiopathic arthritis: what do we know? A systematic review. Rheumatology (Oxford). 2020 Dec 1;59(12):3633-3644. doi: 10.1093/rheumatology/keaa438. PubMed 32940701 ↗
  • Davies K, Cleary G, Foster H, Hutchinson E, Baildam E; British Society of Paediatric and Adolescent Rheumatology. BSPAR Standards of Care for children and young people with juvenile idiopathic arthritis. Rheumatology (Oxford). 2010 Jul;49(7):1406-8. doi: 10.1093/rheumatology/kep460. Epub 2010 Feb 19. No abstract available. PubMed 20173199 ↗
  • Scott C, Chan M, Slamang W, Okong'o L, Petty R, Laxer RM, Katsicas MM, Fredrick F, Chipeta J, Faller G, Pileggi G, Saad-Magalhaes C, Wouters C, Foster HE, Kubchandani R, Ruperto N, Russo R. Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind. Clin Rheumatol. 2019 Feb;38(2):563-575. doi: 10.1007/s10067-018-4304-y. Epub 2018 Sep 28. PubMed 30267356 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05696340
Lead sponsor
University Hospital, Clermont-Ferrand
Collaborators
Research on Healthcare Performance Lab U1290
Responsible party
Sponsor
First posted
Jan 25, 2023
Start date
Oct 18, 2022
Primary completion
Sep 2023 (estimated)
Completion
Sep 2023 (estimated)
Last update
Jan 25, 2023

Study contacts

Lise LACLAUTRE
Contact
promo_interne_drci@chu-clermontferrand.fr
334.73.754.963
Aurélie CHAUSSET
study director · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion